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Insulin resistance predicts rapid virological response in non-diabetic,
non-cirrhotic genotype 1 HCV patients treated with peginterferon
alpha-2b plus ribavirin: Some issues
To the Editor:
We read with great interest the report by Grasso et al. in a recent
issue of the Journal of Hepatology [1]. They enrolled 90 consecu-
tive, non-diabetic, non-cirrhotic patients with genotype 1 chronic
hepatitis C, treated with peginterferon alpha-2b plus ribavirin.
Two issues need clariﬁcation.
The ﬁrst concerns the unit of sensitivity of the qualitative
reverse-transcription PCR test, Roche Cobas Amplicor assay
which was mistakenly written as copies per millilitre in this
paper. It should be international units per millilitre [2].
Secondly, rapid virological response (RVR) [3,4] and homeo-
stasis model assessment of insulin resistance (HOMA-IR) [5,6]
have been important factors associated with achievement of a
sustained virological response (SVR). However, the current study
observed that HOMA-IR could predict rapid virological response
(RVR) but not SVR [1]. There is low probability of normal distri-
bution for HOMA-IR. For example, the mean value and standard
deviation of HOMA-IR was 2.6 and 2.1, respectively, in the cur-
rent study. Therefore, non-parametric inferential statistical
methods or logarithmic transformation of original values to
improve skewness before analyses are preferred in this situation.
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Letters to the EditorInsulin resistance predicts rapid virological response in
non-diabetic, non-cirrhotic genotype 1 HCV patients treated with
peginterferon alpha-2b plus ribavirin: A clariﬁcationTo the Editor:
We read with interest the comment by Wu and colleagues on our
recently published paper [1]. Two issues indeed need to be clariﬁed.
The unit of sensitivity of the qualitative reverse-transcription
PCR test, Roche Cobas Amplicor assay, was mistakenly reported
inthePatientsandmethodssectionascopiespermillilitre, ratherthan
as international units per millilitre. We apologize for this oversight.
Regarding the second issue, although equal variance was
found between the two groups (SVR and no-SVR), when theJournal of HepatologyLevene test was applied to HOMA-IR, a Kolmogorov–Smirnov
test conﬁrmed a non-normal distribution of HOMA-IR values,
as suggested by Wu and colleagues. The Mann–Whitney test,
which had actually been applied in our former analysis, failed
to demonstrate a signiﬁcant difference in HOMA-IR between
patients with and without SVR, although the p-value was
slightly better than the one reported in Table 1. Nevertheless,
we agree that this clariﬁcation should have been included in
the statistical analysis section.2010 vol. 52 | 305–307
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co-infected patients
To the Editor:
In the recently published article by Merchante et al. [1] insulin
resistance, analyzed as HOMA value [(fasting insulin mU/
ml  fasting glucose mmol/l)/22.5)], was not associated with sus-
tained virologic response (SVR) to anti-HCV combination therapy
in HIV/HCV co-infected patients. In that retrospective cohort
study, 36% of 155 patients achieved SVR. At multivariate analysis,
HCV genotype 3, lower baseline HCV-RNA and higher baseline
LDL-cholesterol were independently correlated to SVR. On the
contrary, the HOMA index, considering a cut-off of 4, did not
show any correlation with SVR, even after excluding cirrhotic
patients from the analysis.
In our clinic, we retrospectively analyzed 86 HIV/HCV co-
infected patients treated with Peg-IFN with RBV. At HCV treat-
ment initiation their median age was 42 years, 67% were males,
77% injecting drug users, 88% on combination anti-retroviral
treatment (cART), their median CD4 was 478 cells/mm3; 85%
had HCV-RNA >400,000 IU/ml, 33% with HCV genotype 3, 64%
HCV genotype 1 or 4; 30% showed a Metavir ﬁbrosis score of
F3–F4. Patients were treated with Peg-IFN + RBV (80% Peg-IFN
a2a) for a median of 43.1 weeks (41% of patients reaching
48 weeks of treatment). Fasting IR was determined at baseline,
12 and 48 weeks of HCV therapy. IR was calculated using the
HOMA index (IRP 2.6), Quicki index (IR 60.33) and McAuley
index (IR 65.8) and the different values were correlated with
early virologic response (12 weeks, EVR), end of treatment
response (ETR) and sustained virological response (SVR) by logis-
tic regression analysis. EVR was achieved in 67.4%, ETR in 66.2%,
SVR in 37.2%. IR at baseline 12 and 48 weeks was 2.0 (Q1–Q3 1.4–
3.3), 2.1 (1.4–3.3) and 2.1 (1.3–4.1), according to HOMA index;
0.34 (0.32–0.36), 0.34 (0.32–0.36) and 0.34 (0.31–0.37) according
to Quicki index and 6.4 (5.3–7.3), 5.9 (4.6–7.1) and 6.0 (4.7–7.5),
according to McAuley index, respectively. No signiﬁcant longitu-
dinal changes of the IR indexes were observed. HCV genotype 3
was weakly associated with a lower baseline McAuley index
(mean difference 0.77 p = 0.06). Genotype 3 was the only vari-
able signiﬁcantly associated with any type of response: EVR
(OR vs genotype 1 or 4: 6.6, 95%CI 2.1–21), ETR (8.38;2.66–
26.41) and SVR (6.96;2.81–17.23). Moreover, baseline HCV-
RNA <400,000 IU/ml also signiﬁcantly predicted SVR (OR 0.22;
0.07–0.70). Concerning IR measures, only baseline or week 12
Quicki index 60.33 showed a slight correlation with reduced
probability of ETR (p = 0.048), while no other IR index showed
an association with any other end-point, even in the analysis
stratiﬁed by viral genotype (see Table 1).
Our data showed similar results compared with those of
Merchante et al. The two case series are quite similar for baseline
characteristics, as well as for outcomes of anti-HCV treatment
(36% vs 37.2% of SVR), suggesting the absence of relevant biases.
In both studies IR was not correlated with anti-HCV treatment
response, considering not only SVR, as Merchante et al. did, but
also EVR and ETR as we did. Moreover, we tried to explore IR
indexes other than HOMA (Quicki and McAuley) failing to ﬁnd
any relevant correlation with treatment outcome except for a
slight association between Quicki index and ETR. In agreement
with the study of Merchante et al. our study conﬁrms the lack
of a relevant role of IR in predicting SVR in HIV/HCV co-infected
patients. Moreover, our data indicate that IR does not predict
virological response to anti-HCV treatment in any HCV genotype
group.
In contrast to these studies, Nasta and coworkers [2] identi-
ﬁed a signiﬁcant association between IR and rapid virological
response (RVR, achievement of undetectable HCV-RNA at week
4: 27% of probability in patients with IR vs 54% in those without).
They did not evaluate either ETR or SVR, so that we cannot spec-
ulate about the consistency of the results with a more stringent
Table 1. Crude associations of different insulin resistance indexes with virological outcomes of HCV therapy in all HCV/HIV co-infected patients and divided by HCV
genotypes (univariate logistic regression).
All patients Genotype 3 Genotype 1, 4
EVR ETR SVR EVR ETR SVR EVR ETR SVR
HOMA
P2.6
0.69 (0.22–
2.14)
0.60 (0.21–
1.76)
1.29 (0.45–
3.72)
0.77 (0.06–
10.49)
0.18 (0.01–
2.42)
0.67 (0.11–
4.21)
0.71 (0.19–
2.61)
0.83 (0.24–
2.89)
2.30 (0.54–
9.76)
Quicki
60.33
0.47 (0.15–
1.42)
0.34 (0.12–
0.99)
0.69 (0.25–
1.94)
1.27 (0.10–
16.81)
0.29 (0.02–
3.83)
0.24 (0.04–
1.51)
0.37 (0.10–
1.35)
0.34 (0.10–
1.17)
1.36 (0.33–
5.61)
Mc Auley
65.8
0.60 (0.20–
1.84)
0.55 (0.19–
1.58)
1.38 (0.49–
3.88)
0.57 (0.04–
8.05)
0.13 (0.01–
1.87)
1.20 (0.17–
8.66)
0.74 (0.21–
2.62)
0.92 (0.27–
3.08)
2.62 (0.62–
11.19)
Values represent odds ratios (95% conﬁdence intervals). EVR, early virological response; ETR, end of treatment response; SVR, sustained virological response.
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